ArticleEMBO reports2026
Reevaluating the senolytic activity of a GLS1 inhibitor and an anti-PD-1 antibody: toward greater reproducibility and methodological rigor.
Article in EMBO reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Immunological consequences of senescence in physiology and pathology.Journal of translational medicine · 2026Review
- Response to Kawamoto et al.EMBO reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
The discovery of the senescence-associated secretory phenotype (SASP) has reshaped our understanding of cellular senescence, shifting its role from a solely tumor-suppressive mechanism to a potential driver of chronic inflammation and age-related diseases. Accordingly, senolytic drugs, which selectively eliminate senescent cells, have garnered considerable interest due to promising preclinical studies. However, concerns remain regarding the reproducibility and generalizability of these findings. In this cross-laboratory study, we rigorously tested the senolytic efficacy of a GLS1 inhibitor and an anti-PD-1 antibody-agents previously reported to reduce the burden of p16
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.